te
Bio-Techne
TECH
NASDAQ $52.13
How effective is Bio-Techne's capital allocation strategy?
Bio-Techne has mixed capital allocation. Returns on capital are mediocre, suggesting some investments are not generating adequate returns. Management could be more disciplined in deploying shareholder capital.
Read the full report on Bio-Techne and explore the other sections
Overview of Bio-Techne
Does Bio-Techne have a strong competitive moat?
Does Bio-Techne have pricing power in its industry?
How predictable is Bio-Techne's business?
Is Bio-Techne financially strong?
How effective is Bio-Techne's capital allocation strategy?
Does Bio-Techne have high-quality management?
What is the fair value of Bio-Techne stock?